Ethical Considerations Explored for Aducanumab in Alzheimer Disease
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
Alzheimer Disease
Aducanumab Significantly Reduces Tau Pathology, Clinical Decline in Alzheimer Disease
New data evaluating the treatment effect of aducanumab-avwa demonstrated a positive correlation between plasma p-tau reduction and less cognitive and functional decline in Alzheimer disease.
FDA Clears Language Independent Computerized Test to Detect Cognitive Impairment
By using animal images, the test avoids cultural or educational bias and can be used repeatedly with no learning effect.
FDA Assigns PDUFA Date for Donepezil Transdermal System
Adlarity is a once-weekly transdermal formulation of donepezil.
Gantenerumab Designated Breakthrough Therapy for Alzheimer Disease
The FDA has granted Breakthrough Therapy designation to gantenerumab, an anti-amyloid beta antibody, for the treatment of Alzheimer disease.
Levetiracetam Well Tolerated for Alzheimer Disease
Does not improve primary outcome, but did improve performance on certain cognitive tasks in those with epileptiform activity
Eisai Begins Rolling BLA Submission of Lecanemab for Early Alzheimer Disease
Lecanemab is an investigational anti-amyloid beta protofibril antibody.
Aduhelm Label Update Clarifies Patient Population Studied in Trials
The treatment, which is administered as a monthly intravenous infusion, binds to aggregated β-amyloid and promotes removal of amyloid from the brain.
Donanemab Granted Breakthrough Tx Status for Alzheimer Disease
Donanemab is an investigational antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.
Lecanemab Gets Breakthrough Tx Status for Alzheimer Disease
Lecanemab (BAN2401) is an investigational anti-amyloid beta protofibril antibody
for the treatment of Alzheimer disease.
